A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

NCT07230860 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: JNJ-95597528
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC